CAM
XLRN

Congress Asset Management’s Acceleron Pharma XLRN Stock Holding History

Congress Asset Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-17,238
Closed -$987K – 382
2018
Q3 		$987K Buy
17,238
+1,750
+11% +$86K 0.01% 305
2018
Q2 		$751K Hold
15,488
– – 0.01% 315
2018
Q1 		$606K Buy
15,488
+324
+2% +$13.8K 0.01% 337
2017
Q4 		$644K Sell
15,164
-13,125
-46% -$492K 0.01% 335
2017
Q3 		$1.06M Buy
+28,289
New +$982K 0.02% 317

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Congress Asset Management's XLRN Position: Q4 2018 in Review

Congress Asset Management sold out of Acceleron Pharma (XLRN) in Q4 2018, closing a stake of 17,238 shares — an estimated $987K sold.

Congress Asset Management first reported a position in XLRN in Q3 2017 and held it in 5 quarters. The position peaked at $1.06M in Q3 2017. 162 funds tracked by Wall St. Rank hold XLRN as of Q4 2018.

  • Congress Asset Management reported no remaining Acceleron Pharma position as of Q4 2018 after selling out during the quarter.
  • Congress Asset Management sold 17,238 Acceleron Pharma shares in Q4 2018, an estimated $987K.
  • Congress Asset Management first reported a position in Acceleron Pharma in Q3 2017 and held it in 5 quarters.
  • Congress Asset Management's Acceleron Pharma position peaked at $1.06M in Q3 2017.
  • 162 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2018.

Based on Congress Asset Management's 13F filing for Q4 2018, filed 25 Jan 2019.